The supply of GLP-1 drugs has been increasing, but they’re still expensive for most patients. Here are answers to some ...

Clinical trials, traditionally plagued by low success rates and high operational costs, are being reengineered through AI ...

Economists begin by asking what would happen in a completely free market. Then we ask whether government intervention of some ...

Trump’s executive order to cap U.S. costs risks limiting the supply of new pharmaceuticals. President Donald Trump’s ...

Experts said the president's executive order could work in lowering costs, but it won't make for an immediate fix.

In the face of such pressure, pharmaceutical companies are eager to reduce the cost of drug development so that ... and more accurate clinical trial periods. More data and faster analysis mean ...

The Trump administration has put in motion its plan to secure lower prescription drug costs for Americans. This week, the ...

Trump gives the impression that Americans will shortly see steep decreases in what they pay for prescription drugs. But even ...

While Trump has not yet turned to price controls to address America‘s absurdly high drug prices, Monday‘s executive order ...

In the second part of his Pharma Commerce video interview, Kevin Dondarski, Deloitte’s life sciences R&D strategy leader, ...

If the goals of his executive order are achieved, price reductions would not happen “almost immediately,” experts say.

If prescription savings are to be passed on to Americans not on Medicare, Congress likely would have to pass a law to enact ...